CAPR earnings analysis
What we found in CAPR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Capricor reported no revenue and diluted EPS of -$0.70, down from -$0.59 in Q1 2026 and -$0.57 in Q2 2025, while operating expenses rose to $42.9 million from $27.7 million year over year. Free cash flow was -$21 million, although $237.9 million of cash, cash equivalents and marketable securities was expected to fund operating capital requirements for at least twelve months. The 3-to-9 FDA advisory committee vote, the NS distribution dispute moving toward arbitration, and new litigation involving 3 Mesoblast patents materially raise regulatory and commercialization risk.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- $237.9M liquidity supports near-term runway
- Liquidity remained substantial at $237.9 million as of June 30, 2026, consisting of cash, cash equivalents and marketable securities.
- EPS deteriorated sequentially and year over year
- The company reported diluted EPS of -$0.70, compared with -$0.59 in Q1 2026 and -$0.57 in Q2 2025, reflecting deterioration of $0.11 sequentially and $0.13 year over year.
- Cash burn remains significant
- Quarterly free cash flow was -$21 million, indicating continued cash consumption while the company remains pre-commercial.
- Limited near-term interest-rate exposure
- Management said a hypothetical 100-basis-point increase or decrease in interest rates would not materially affect the fair value of the investment portfolio.
- Disclosure controls assessed effective
- Management concluded that disclosure controls and procedures were effective at the reasonable assurance level as of June 30, 2026.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Wider loss and expense escalation
- Q2 diluted EPS of -$0.70 missed the -$0.58 consensus estimate by $0.12, while operating expenses increased to $42.9 million from $27.7 million in the prior-year quarter, a $15.2 million or approximately 55% increase.
- Unfavorable FDA advisory vote
- The FDA advisory committee voted 3 in favor and 9 against effectiveness of Deramiocel for DMD cardiomyopathy. Management said the FDA may issue a complete response letter or delay a decision on the amended BLA.
- Distribution dispute threatens commercialization
- The NS distribution dispute has shifted toward arbitration after Capricor withdrew its preliminary-injunction motion without prejudice; the company estimates arbitration will begin in fall 2026. An adverse outcome could impair commercialization and potential revenue.
- New Deramiocel patent litigation
- Mesoblast filed a patent infringement and declaratory judgment action on July 16, 2026 concerning Deramiocel, asserting infringement of 3 patents and seeking injunctive relief, damages and attorneys' fees.
- Persistent losses and financing need
- Capricor stated that it expects losses to continue for the foreseeable future and may require additional capital to fund trials and development programs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.7
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management stated that $237.9 million of cash, cash equivalents and marketable securities as of June 30, 2026 should fund operating capital requirements for at least the next twelve months; additional outlook depends on regulatory clarity.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 13, 2026
- Capricor Therapeutics reported a troubling Q1 2026 with no revenue recognized, significantly underperforming against expectations of $25.2 million, and a diluted EPS of -$0.59, missing estimates by $0.05. Operating…
- 10-K · March 17, 2026
- Capricor is a clinical-stage biotech focused on Deramiocel (a CDC cell therapy) and an exosome platform (StealthX). The company announced positive Phase 3 HOPE-3 topline results (n=106) with the primary endpoint PUL…
- 10-Q · May 14, 2025
- Capricor reported Q1 2025 revenue of $0 (Q1 2024: $4,906,877) and a net loss of $24,391,594, or $(0.53) per share, versus a net loss of $9,794,073, or $(0.31) in Q1 2024. Operating expenses rose to $24,982,948 (Q1 2024:…
- 10-K · March 26, 2025
- Capricor Therapeutics focuses on developing innovative cell and exosome-based therapies for Duchenne muscular dystrophy (DMD). The company recently completed its Biologics License Application (BLA) submission for its…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CAPR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever